Micro-metastases in stages I and II colon cancer are a predictor of the development of distant metastases and worse disease-free survival

Abstract Approximately 30% of the patients with Dukes A/B colon carcinoma will develop loco-regional recurrence or distant metastases. The aim of this study was to evaluate if patients with micro-metastases are at higher risk for developing distant metastases and therefore a worse disease-free survi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology Vol. 35; no. 5; pp. 492 - 496
Main Authors: van Schaik, P.M, Hermans, E, van der Linden, J.C, Pruijt, J.R.M, Ernst, M.F, Bosscha, K
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-05-2009
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Approximately 30% of the patients with Dukes A/B colon carcinoma will develop loco-regional recurrence or distant metastases. The aim of this study was to evaluate if patients with micro-metastases are at higher risk for developing distant metastases and therefore a worse disease-free survival and overall survival. In the period January 2000–January 2002, 137 patients underwent curative surgery for colon cancer. When patients had a Dukes A/B colon carcinoma, additional staining and sectioning on the harvested lymph nodes were performed retrospectively. Lymph nodes were examined using 4 multilevel sections at 250-μm intervals and stained with Pan-Cytokeratin. There were 11 patients with a Dukes A and 61 patients with a Dukes B colon carcinoma. Twenty-two patients developed metastases in time (group I) whereas 50 patients did not (group II). After additional staining and sectioning 41% of the patients of group I and 16% of the patients of group II showed micro-metastases ( p < 0.05). The 5-year overall survival rate in the group with micro-metastases was 62% against 79% in the group without micro-metastases. The disease-free survival (DFS) was 51% and 72% ( p < 0.05), respectively. Patients with micro-metastases develop significant more distant metastases in time and have a significant worse DFS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2008.07.011